ValiRx PLC
LSE:VAL

Watchlist Manager
ValiRx PLC Logo
ValiRx PLC
LSE:VAL
Watchlist
Price: 0.374 GBX -2.86% Market Closed
Market Cap: 2.8m GBP

Operating Margin

-40.5%
Current
Improving
by 97.7%
vs 3-y average of -138.2%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-40.5%
=
Operating Income
£-2m
/
Revenue
£49.8k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-40.5%
=
Operating Income
GBX-2m
/
Revenue
£49.8k

Peer Comparison

Country Company Market Cap Operating
Margin
UK
ValiRx PLC
LSE:VAL
2.9m GBP
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
386.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
163.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.6B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.4B USD
Loading...

Market Distribution

Lower than 95% of companies in United Kingdom
Percentile
5th
Based on 3 579 companies
5th percentile
-40.5%
Low
-195 650% — 0%
Typical Range
0% — 0.2%
High
0.2% — 4 630.7%
Distribution Statistics
United Kingdom
Min -195 650%
30th Percentile 0%
Median 0.1%
70th Percentile 0.2%
Max 4 630.7%

ValiRx PLC
Glance View

Market Cap
2.8m GBX
Industry
Biotechnology

ValiRx Plc is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards commercialization and partnering. The company is headquartered in Nuneaton, Warwickshire and currently employs 10 full-time employees. The company went IPO on 2000-02-28. The firm is engaged in the development of oncology therapeutics and companion diagnostics. The company focuses on the development of treatments in cancer and women’s health. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. Its VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer. Its VAL301 for the treatment of women with endometriosis. Its VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. Its BC201 is a combination of the peptide ingredient of VAL201 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. The company operates through divisional companies, including ValiPharma and ValiSeek.

VAL Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-40.5%
=
Operating Income
£-2m
/
Revenue
£49.8k
What is ValiRx PLC's current Operating Margin?

The current Operating Margin for ValiRx PLC is -40.5%, which is above its 3-year median of -138.2%.

How has Operating Margin changed over time?

Over the last 2 years, ValiRx PLC’s Operating Margin has increased from -23 942.7% to -40.5%. During this period, it reached a low of -23 942.7% on Dec 31, 2023 and a high of -4 051.4% on Jul 30, 2025.

Back to Top